Safety study of STR-P005 immunotherapy in lupus
Part of Immune system & allergy clinical trials.
This early-stage trial tests a new cell-targeting treatment called STR-P005 in adults with lupus. The study will check whether it is safe and how well it works for people with lupus who have a specific type of immune cell (CD19-positive B cells) in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed CD19-positive B cells in your blood (checked by lab test)
- Healthy heart, lungs, liver, and kidneys, with adequate blood counts
- No recent treatment with steroids (high doses), immune-suppressing drugs, or cell therapies
- No active infections, blood clots, uncontrolled diabetes, or history of heart disease in the last 6 months
- Not pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
This trial tests an investigational drug (STR-P004) given by IV to treat kidney diseases caused by the immune system. It aims to see if the drug is safe and tolerable for patients with conditions like lupus nephritis or ANCA vasculitis.
This trial tests a new treatment called KN5501 (a type of cell therapy) for people with lupus that hasn't been controlled by usual medicines. It aims to see if this treatment can help calm the immune system and reduce lupus activity.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.